GLP-1Analogue Liraglutide Suppress The Proliferation Of CD4~+CD25~-T Cells In Type1Diabetic Patients

Objective To study the role of the GLP-1analogue liraglutide on the proliferation of CD4+CD25" T cells in healthy people and type1diabetic patients in vitro, and evaluate the probable immune regulatory role of liraglutide on the therapy of type1diabetes.Methods CD4+CD25" T cells in10healthy people and10newly-onset type1diabetic patients were separated from peripheral blood by MACS immune-magnetic beads and stimulated by Human T-Activator CD3/CD28Dynabeads to proliferate. CFSE labeling technique was used to evaluate the proliferation of CD4+CD25-T cells by flow cytometry. Liraglutide at different concentrations (0nmol/mL,25nmol/mL,50nmol/mL,100nmol/mL) were added to the proliferative system, then the proliferation of CD4+CD25-T cell were measured.Results (1) Without liraglutide, upon stimulation with CD3/CD28Dynabeads, the proliferation of CD4+CD25-T cells in type1diabetic patients was much more robust than that in healthy people (P<0.01).(2) Liraglutide suppressed the proliferation of CD4+CD25-T cells in either healthy people or type1diabetic patients with dose-dependent manner (P<0.05).(3) The inhibitory effects of liraglutide on CD4+CD25-T cells proliferation in healthy people and type1diabetic patients were similar (P>0.05).Conclusion The proliferation of CD4+CD25-T cells in type1diabetic patients was more robust than that in healthy people, which indicated there are cellular immune dysfunction in type1diabetes. Liraglutide can obviously inhibit the proliferation of CD4+CD25-T cells in type1diabetic patients in vitro. The immunosuppression effect of liraglutide may be applied to the treatment of type1diabetes.